Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Paroxysmal Nocturnal Hemoglobinuria: A Complement-Mediated Hemolytic Anemia

    ... largely mediated by the alternative pathway of complement. Clinical manifestations result from the lack of specific cell surface ... Complement inhibition strategies are an area of active research. Bone Marrow Diseases:  ...

    Research Article last updated 06/23/2015 - 9:32am.

  2. Treatments

    ... cure".   Clinical Trials Clinical research is at the heart of all medical advances, identifying new ways to ...

    Topic section last updated 02/16/2017 - 3:04pm.

  3. Genetics factors associated with myelodysplastic syndromes

    ... miR-125a and MiR-21. Somatic mutations may influence the clinical phenotype but are not included in current prognostic scoring systems. In recent years research has brought new insights into these diseases, but few of the findings ...

    Research Article last updated 06/03/2015 - 11:30am.

  4. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?

    ... many patients do not derive benefit. There is an urgent clinical need to identify patients with low probability of benefiting from ... therapies in patients with MDS remains a top clinical and a research priority. Bone Marrow Diseases:  ...

    Research Article last updated 03/03/2015 - 1:03pm.

  5. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies

    ... recognized as a distinct entity with unique biologic and clinical features. This change has created a scientific and clinical research landscape that makes it difficult to discern CMML-specific validated ...

    Research Article last updated 03/02/2015 - 1:22pm.

  6. Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia

    ... their unrelated donors who had pre-HCT blood samples and clinical and outcome data available at the Center for International Blood and Marrow Transplant Research. Patients underwent HCT between 1989 and 2007 in 84 centers and were ...

    Research Article last updated 03/03/2015 - 11:48am.

  7. Myelodysplastic syndromes in the United States: an update for clinicians

    ... most often in elderly white persons. MDS have significant clinical consequences, including cytopenias leading to infection, bleeding, ... morbidity and mortality in elderly patients. Recent research suggests MDS occurs more frequently than previously thought and may ...

    Research Article last updated 04/23/2014 - 11:46am.

  8. What MDS Patients Should Know About Clinical Trials

    ... Do you find that some patients don’t understand what clinical trials are? There’s a wide range of patient knowledge and ... ask me about them because they want to be part of the latest research and latest opportunities to try new drugs or drug combinations for ...

    Interview last updated 11/13/2015 - 11:12am.

  9. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?

    ... Anemia remains the most challenging clinical manifestation to treat in patients with lower-risk ... chromosomal abnormality. Lenalidomide also has meaningful clinical activity in lower-risk patients without deletion 5q. The experience ... in MDS is a modern example of reciprocal translational research, in which bench work led to an approved drug for patients, and ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

    ... toxicity and relapse rates is another area of active research. SUMMARY: Sequential switching to the alternative HMA, clinical trials of novel targeted therapies, azacitidine-based combination ...

    Research Article last updated 01/08/2014 - 9:15am.